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ABSTRACT 
Influenza, known as the ‘flu’, is a recurrent acute viral infection that might cause severe 
inflammation, particularly in vulnerable individuals, i.e. young children, the elderly, and 
immune-suppressed patients, such as stem cell transplant recipients. Prevention strategies, 
primarily vaccination, and possibly the use of anti-viral drugs, are recommended with the aim 
to reduce mortality and morbidity. Influenza vaccination responses are often sub-optimal in 
immune-compromised patients. There is therefore a need to evaluate other vaccination 
systems and schedules to improve vaccine efficacy.  
We mapped the humoral and cellular anti-flu directed immune responses and studied in a first 
set of experiments the immune responses in immune competent individuals prior to, and 
following a natural pandemic influenza infection, as well as after adjuvanted Pandemrix
®
 
influenza vaccination. This was performed prospectively during the H1N1 pandemic 
influenza of 2009. ‘High content’ influenza proteome peptide arrays were used to gauge 
serum IgG epitope signatures prior to and after Pandemrix
®
 vaccination/ or H1N1 pandemic 
infection described in paper I. A novel epitope residing in the sialic acid receptor-binding 
domain of VEPGDKITFEATGNL (251-265) of the pandemic flu hemagglutinin was 
identified. This epitope was found to be exclusively recognized in serum from previously 
vaccinated individuals and never in serum from individuals with H1N1 infection. The natural 
H1N1 infection induced a different footprint of IgG epitope recognition patterns as compared 
to the Pandemrix
®
 H1N1 vaccination. 
Pre-transplant influenza vaccination of the donor or allogeneic hematopoietic stem cell 
(HSCT) candidate was evaluated in a randomized study of 122 HSCT patients reported in 
paper II. The antibody titers against H1 (p=0.028) and H3 (p<0.001) were highest in the pre-
transplant recipient vaccination group until d.180 after transplantation. A significant 
difference was found concerning the specific Ig levels against pandemic H1N1 at 6 months 
after HSCT (p=0.02). The mean IgG levels against pandemic H1N1, generic H1N1 and 
H3N2 were highest in the pre-transplant recipient vaccination group. Pre-transplant influenza 
vaccination of the donor or the HSCT candidate was found to be beneficial in eliciting 
seroprotective titers. 
The immunogenicity after a single dose of adjuvanted trivalent virosomal vaccination was 
evaluated in a cohort of 21 HSCT recipients and compared to a control cohort of 30 HSCT 
recipients who received a single dose of non-adjuvanted seasonal trivalent subunit 
vaccination, reported in Paper III. The delta change of IFNγ production in response to 
pandemic influenza H1N1 (p=0.005) and influenza B antigens (p=0.01) were significantly 
increased in blood from individuals who received the virosomal, as compared to the non-
adjuvanted vaccine. Virosomal vaccination was found to be beneficial in eliciting robust 
cellular immune responses to influenza pandemic H1N1. 
Pandemic influenza hemagglutinin MHC class 1 peptide restricted CD8 T-cells were 
enumerated over the course of a natural pandemic influenza infection and Pandemrix
®
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vaccination in a prospective study reported in Paper IV. PBMCs from vaccinated control 
individuals exhibited a significantly increased percentage of (p=0.003) hemagglutinin 
specific CD8 T-cells that resided in the terminally differentiated effector memory 
compartment, as compared to PBMCs from individuals that contracted H1N1 infection. The 
cellular immune signatures were found to be different elicited by a natural flu infection as 
compared to vaccination concerning the phenotype/maturation of antigen-specific CD8 T-
cells. 
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1 INTRODUCTION 
1.1 The immune response 
The consolidated effort procured by molecules, organelles, cells and tissues, in preventing 
infection and eliminating transformed cells, represents the immune response, which is crucial 
for survival. Severely immundeficient individuals are highly susceptible to infections and 
thereby more likely succumb to a range of viral, bacterial and fungal diseases, if no 
therapeutic intervention is provided. The cells and tissues of the human immune system vary 
in complexity and function, starting from the very basic protection, elaborated by skin 
epithelial and mucosal surfaces, to highly complex and specialized adaptable immune cells, 
capable of immunological memory. Each of these components contributes with specialized 
roles involved in fighting off infections, prevention of tumors, recognizing and mediating 
allograft and foreign tissue rejection. The immune response can be divided into two arms; one 
arm that is quick to respond to pathogens is referred to as innate immunity. The second arm 
represents the adaptive immune response that usually develops slowly and evolves upon 
subsequent encounters with the nominal pathogen(s). 
1.2 Innate immune response 
The innate immune response is characterized by a defined set of reactions to invading 
microbes and pathogens. These can be broadly classified into inflammation and anti-viral 
defense mechanisms on the basis of germ-line coded receptors that are ‘non-specific’ 
concerning recognition of microbial pathogens [1]. Receptors sensing invading pathogens are 
referred to as pattern recognition receptors (PRR) and are widely distributed on different cell 
types [2]. A broad array of pathogen derived molecules are recognized by these receptors; 
these patterns are referred to as pathogen associated molecular patterns (PAMPS) [2]. PRRs 
can for example be secreted as mannan-binding lectin (MBL), C-reactive protein and serum 
amyloid proteins. They can also be found on the cell surface, such as the macrophage 
scavenger receptor with a broad specificity to many ligands including dsRNA, LPS, LTA [3] 
or may be located intracellularly, such as the protein kinase PKR, OAS/RNaseL systems and 
the family of NOD-like receptor proteins [4-6]. The NOD like receptors, especially the 
NLRP-3, are important components of the inflammasome that releases the mature form of IL-
1β after its engagement with the nominal target, resulting in acute inflammation [7]. 
Apart from these PRRs, ten biologically relevant toll-like receptors (TLRs) have been 
identified, for instance the extracellular receptors, e.g. TLR4, which is a critical LPS sensing 
receptor [8]. TLR2 recognizes peptidoglycan and bacterial lipoproteins [9], TLR5 recognizes 
bacterial flagellin [10]. Intracellular receptors, e.g. TLR9 recognizes unmethylated CPG 
motifs in DNA [11] and the TLRs 3, 7, 8 that recognize viral nucleic acids (dsRNA) [12]. 
The recognition of their cognate ligands sets off a downstream signaling pathway leading to 
the activation of the NF-κB transcription factor which consequently leads to cytokine 
production, particularly IFNα/β and to increased  expression of co-stimulatory molecules 
[13]. 
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Once activated by the corresponding PRR receptors, phagocytes, including neutrophils and 
monocytes/macrophages, enter the site of infection, where they ingest microbial pathogens. 
The polymorphonuclear (PMNs) leukocytes in blood (neutrophils) are exceptionally efficient 
in phagocytosis of bacterial and fungal pathogens. The blood monocytes enter into 
extravascular spaces and differentiate into resident macrophages for e.g microglia (CNS), into 
Kupffer cells (liver), alveolar macrophages (lungs), osteoclasts (bone); these cells are 
programmed to survive in their tissue environments, unlike neutrophils that succumb after 
ingestion of their targets [14]. 
Macrophages may differentiate into subsets with distinct functions associated with the nature 
of the stimulation. For instance, activation by either PRRs or effector cytokines such as IFNγ 
promotes “classically activated” M1 macrophages. These M1 macrophages are pro-
inflammatory and mediate host defence against bacteria, viruses, protozoa and to some extent 
antitumor responses. M2 macrophages are anti-inflammatory and promote wound repair. 
Regulatory macrophages secrete copious amounts of IL-10 in response to Fc receptor-γ 
ligation. Myeloid-derived suppressor cell (MDSCs) maybe precursors to tumor associated 
macrophages (TAM) that suppress antitumor immune responses. The M2, regulatory, TAM 
and MDSC subsets of macrophages promote immune suppressive activity [15]. 
However, macrophages adopt context dependent phenotypes that can either promote or 
inhibit immune responses and may represent a spectrum of activated phenotypes, rather than 
discrete stable fates. Many studies describe plasticity in macrophages switching from one 
phenotype to another in response to the local cytokine milieu. Some macrophage effector 
functions may combine activities that have classically been labelled as an M1 or M2 response 
[14, 16]. 
M1 macrophages (i) produce cytokines such as TNF, IL-1, IL-6 and IL-12 that increase 
inflammation and aid adaptive immune responses, they also (ii) secrete reactive oxygen 
species (ROS) and nitric oxide (iNOS) (iii) upregulate the MHC class I and II machinery.  
M2 macrophages have pronounced anti-inflammatory effects including wound repair and 
fibrosis, predominantly through production of TGF-β and IL-10 [16]. 
Dendritic cells are cell subsets that bridge the innate and adaptive immune responses; they 
recognize microbes and subsequently produce cytokines and display microbial peptide 
antigens on their cell surface that may activate the adaptive cellular immune response [17]. 
Mast cells, derived from the myeloid lineage, have abundant cytoplasmic granules that 
contain histamines and heparin. These cells play a major role in allergy, anaphylaxis and 
defense against helminthes [18]. 
Natural killer (NK) cells are critical players in an innate immune response; they contain 
abundant cytoplasmic granules effective in killing infected cells. Their killing mechanisms 
are very similar to those seen in cytotoxic CD8 T-lymphocytes. Their functions are evident in 
anti-viral responses, where they synergistically act with macrophages to eliminate 
intracellular viral reservoirs. Activated NK cells produce IFNγ that acts on macrophages by 
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increasing antigen presentation pathways. Production of IL-12, IL-15 and type 1 interferons 
by macrophages play a pivotal role in NK cell development and proliferation. NK cells 
display a host of activating and inhibitory receptors.  
The activating receptors consist of NKG2D and KIRs (killer cell immunoglobulin-like 
receptors) (KIR2DL4, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DS1) 
which recognize stressed cells in conjunction with MHC class I, these receptors have 
signaling subunits called ITAMs (immune receptor tyrosine-based activation motifs) which 
get phosphorylated and activate cytoplasmic tyrosine kinases leading to cytotoxic granule and 
IFNγ release [19, 20]. Another activating receptor is the CD16 (FcγRIII) that is specific for 
IgG antibodies, its activation causes the discharge of cytotoxic granules and is instrumental in 
ADCC (antibody dependent cell cytotoxicity)[21]. 
The inhibitory receptors consist of KIRs (KIR2DL1, KIR2DL2/3, KIR2DL5, and KIR3DL2) 
which may be crucial to the “missing-self hypothesis” which states that NK cells 
preferentially kill cells with missing or compromised self MHC class I expression [22-24]. 
The other well characterized receptor is the CD94-NKG2 receptor that recognizes the non-
classical MHC molecule such as HLA-E [25]. The inhibitory receptors, when activated by 
MHC class I, contain in their cytoplasmic domains signaling units known as ITIMs (immune 
receptor tyrosine-based inhibition motifs) that are phosphorylated and activate cytoplasmic 
tyrosine phosphatases that remove phosphate groups from ITAMS preventing activation 
cascade [20]. 
Non-conventional T-lymphocytes represent a subset of cells already capable of cytokine 
production and cytolytic function as they emerge from the thymus; they exhibit limited 
diversity in their antigen recognition receptors. These correspond to three major cell types 
MAIT cells, γδ T-cells and NKT cells, which are at the interface of innate and adaptive 
immune response. MAIT cells (mucosal associated invariant T-cells) are present in mucosal 
surfaces and restricted to MR1 (MHC related class I-like molecule) that presents vitamin B 
metabolites. These cells may be important in response to pathogenic and commensal bacteria 
[26, 27]. γδ T-cells are mostly CD1 restricted and recognize phospoantigens, they may have 
anti-viral cytolytic functions [28]. In particular, Vγ9Vδ2 T-cells were described to exhibit 
anti-influenza reactivity [29]. Natural killer T-cells (NKT) recognize endogenous and 
exogenous lipid antigens presented by CD1d molecules on APCs [30], the best characterized 
are the type 1 NKT cells that express a restricted TCR with an invariant α chain (Vα24-Jα18) 
paired with a limited array of TCR Vβ chains. These cells have been described to contain 
inflammation - which could lead to lung injury by selectively lysing inflammatory monocytes 
during a severe influenza infection in a CD1d dependent manner [31]. 
Innate lymphoid cells (ILCs) are a heterogeneous cell populations playing a critical role in 
intestinal and mucosal immunity with some subsets even producing cytokines such as IL-5, 
IL-13, IL-22 and/or IL-17A [32]. These cells have been described to drive Th2 associated 
immune response against helminth infections [33] and more recently in the context of acute 
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influenza infection, where they were shown to restore tissue homeostasis and airway 
epithelial integrity after flu infection [34]. 
The complement system is an evolutionary ancient form of host defence that is organized into 
proteolytic cascades leading to inflammation, lysis and opsonization of pathogens. The 
complement system can be activated by three pathways i.e. (i) the classical pathway – is 
initiated when the C1q complex along with C1r and C1s binds to the Fc region of IgG1 and 
IgM antibodies that are bound to pathogens, (ii) alternate pathway – is initiated by the 
pathogenic surface itself (iii) lectin pathway- is initiated by MBL receptor when it recognizes 
PAMPs. All of these pathways lead to production of C3a and further C3b which activates the 
late complement cascade and culminates in the formation of membrane attack complex 
(MAC), this complex is efficient in lysis of thin walled microbial pathogens [35]. 
1.3 Adaptive immune response 
The innate immune responses set the stage for the adaptive or acquired immune response by 
upregulating the expression of co-stimulatory molecules and by increased cytokine 
production. Adaptive immune responses are specific, directed to the microbe and often long 
lived. They can be recalled faster during second and subsequent encounters with the cognate 
pathogen. The two main components of an adaptive immune response are the (i) cellular 
immune response characterized by thymus educated T-lymphocytes and their effector 
cytokines that specifically act on intracellular and phagocytized pathogens. (ii) Humoral 
responses, elaborated by B-lymphocytes that produce antibodies, targeting pathogens in 
extracellular spaces.  
1.3.1 T-cell mediated immune responses 
These responses are defined by T-lymphocytes and are critical in the elimination of 
intracellular pathogens. There are two ways in which the intracellular pathogens may survive 
(i) pathogens, e.g. intracellular bacteria are phagocytosed by macrophages and continue to 
multiply in the cytosol by evading the phagolysosome complex. (ii) Viral pathogens that 
infect non-phagocytic cells such as epithelial cells. In addition to elimination of intracellular 
pathogens, classes of T-lymphocytes expressing the CD4 co-receptor are called helper T-
cells; orchestrate both cellular and humoral responses by producing cytokines (see below in 
section 1.3.1.1). 
1.3.1.1 CD4 T-Lymphocytes 
The CD4 T-lymphocytes are central to immune protection from pathogens; they provide help 
to B cells (for maturation and differentiation and to secrete antibodies), activate macrophages 
and direct PMNs to sites of infection. The naïve CD4 T-lymphocytes patrolling the lymph 
nodes are activated by their T-cell receptor (TCR) complex via the major histocompatibility 
class (MHC) II molecules on the surface of dendritic cells that present microbial peptide 
antigens, usually 10-30 amino acids. The peripheral lymph nodes sample protein antigens 
from epithelial and connective tissues, whereas the blood borne antigens are concentrated by 
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the spleen. These antigens are processed via the MHC class I or II pathways by professional 
antigen presenting cells (APCs) e.g. dendritic cells, macrophages and B-cells. When dendritic 
cell encounter antigens - and are sufficiently stimulated by PRRs - they express a chemokine 
receptor CCR7 and start migrating towards peripheral lymph nodes. In this process, they 
mature into APCs that can very effectively stimulate T-cells. In brief, the MHC II pathway is 
initiated by the active uptake of extracellular protein into the endocytic vesicles of the APCs; 
these internalized proteins are processed into many unique small peptide fragments by the 
fusion of the endosomal and lysosomal vesicles. Following this processing, the newly 
synthesized MHC II αβ dimer, along with an invariant chain containing the CLIP peptide that 
is strongly bound to the peptide binding cleft of the MHC II, are transported to the late 
endosomal vesicle containing the processed peptide fragments.  The late endosomal vesicle 
contains another MHC II like complex, called HLA-DM, which facilitates the exchange of 
the CLIP peptide for higher affinity antigenic peptides. The antigenic peptide is then bound to 
the groove of the MHC II molecule which stabilizes the complex and this is further 
transported to the cell surface in wait for potential CD4 TCR engagement in the lymph nodes 
[36].  
Once the T-cell receptor complex, along with the CD4 co-receptor, is engaged to its cognate 
peptide MHC class II on APCs, a second co-stimulatory CD28 receptor on T-cells may bind 
to the B7.1/7.2 ligands on the APC to complete activation. This activation signals leads to the 
maturation and differentiation of naïve CD4 T-cells into four different possible fates i.e Th1, 
Th2, Th17 and Tregs. Each fate is specialized and committed to produce a certain set of 
cytokines and transcription factors as indicated below. More different subsets have been 
reported recently like Tfh (follicular helper T-cells that provide specialized help to B-cells 
and help in the maintenance and formation of germinal centers [37]), Th9 (polarized in the 
presence of TGF-β/IL-4, producing IL-9 that contributes to anti-parasite responses [38]) and 
Th22 (skin homing cells polarized in the presence of IL-6/TNF-α,producing IL-22 [39]).  
Naïve CD4 T-cells are polarized into a Th1 subset in the presence of IL-12, IL-18 or IFNγ 
when activated by a TCR stimulus in conjunction with peptide MHC class II. Th1 cells have 
been described to be effective in responses against intracellular pathogens; their signature 
cytokines are IFNγ, IL-2 and lymphotoxin α. The transcription factors that defines this subset 
is T-bet and STAT5. IFNγ is a potent activator of macrophages and increases the 
antimicrobial activity of macrophages (described above) and IL-2 is critical for T-cell 
memory formation. 
Th2 cells are subsets that have effective response to extracellular pathogens and helminthic 
infections; CD4 T-cells are often polarized into Th2 cells in the presence of IL-2 and IL-4. 
The signature cytokine(s) produced by this subset are IL-4, IL-5 and IL-13. Th2 cells have 
GATA3 and STAT6 as their transcription factors. IL-4 is a crucial cytokine in inducing IgE 
class switching in B-cells. Particularly IL-5 is involved in the development and activation of 
eosinophils and mast cells. IgE binds to the FcεR1 on basophils and mast cells leading to 
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secretion of histamines setting up an inflammatory milieu. IL-13 is described to be crucial in 
clearing helminthic infections [40]. 
Th17 cells are polarized cells in the presence of IL-6 and TGF-β and play a major role in 
responses against extracellular bacteria and fungi. Their effector signature cytokines are IL-
17a, IL-17f and IL-21 and their transcription factors are RORγt and STAT3. IL-17a and IL-
17f are both critical in recruiting and activating neutrophils to sites of infection; IL-21 acts on 
Th17 cells further promoting the survival of this subset in an autocrine manner. IL-21 also 
has profound effects on CD8 T-cells, B-cells and NK cells e.g. by rescuing cells from 
activation-induced cell death [41]. 
Treg cells are generated in the presence of TGF-β and IL-2 and play a major role in 
promoting self-tolerance and regulating immune responses. The signature cytokines produced 
by these cells are IL-10 and TGF-β, their respective transcription factors are FOXP3 and 
STAT5 [42]. 
1.3.1.2 CD8 T-Lymphocytes 
CD8 T-cells are lymphocytes derived from the bone marrow and are educated in the thymus 
bearing a TCR and CD8 co-receptor. These cells primarily recognize pathogen derived 
peptide MHC class I complexes on the surface of nucleated cells. A requirement for the 
activation of CD8 T-cells is the cross presentation of cytoplasmic antigens by dendritic cells. 
Dendritic cells generally ingest virus-infected cells and process and present peptide antigens 
in the cytosol via the MHC class I to CD8 T-cells [43]. 
The MHC class I complex is a dimer of a heavy α chain noncovalently linked to a protein (β2-
microglobulin) generally expressed on all nucleated cells. The heavy α chain is composed of 
α1 and α2 subunits that form the peptide binding cleft which usually holds an 8-10 mer 
peptide fragment, the α3 subunit that interacts with the CD8 co-receptor during the TCR 
engagement. The MHC class I pathway is initiated by the antigenic proteins in the cytosol, 
e.g. by viral proteins in the infected cell, in addition to the cell’s own misfolded proteins that 
are targeted for destruction by a ubiquitin-proteasome pathway. These proteins are unfolded 
and tagged with ubiquitin and then processed through a proteasome complex that cleaves the 
parent protein into small peptide fragments (8-10aa) in the cytosol. Since the MHC class I 
machinery is synthesized in the endoplasmic reticulum (ER), the peptide fragments are 
transported by a specialized molecules called transport associated with antigen processing 
(TAP), located in the ER. The TAP protein actively pumps peptide fragments from the 
cytosolic side into the ER, where the newly synthesized pre-mature MHC class I heavy α 
chain linked to tapasin is present. The tapasin links the MHC class I α chain to the TAP 
complex and if there are peptides with high affinity, the whole complex is stabilized along 
with β2-microglobulin; the mature MHC class I/peptide/beta-2 microglobulin complex is 
unlinked from TAP and released to the cell surface [36] . 
Upon activation, CD8 T-cells express a broad repertoire of effector molecules in defense 
against microbial pathogens; of importance is the direct cytotoxic effect of target cells due to 
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release of perforin and granzymes. Perforin is an effective disruptor of target cell membranes 
facilitating the entry of granzymes in particular granzyme B that activates caspases which 
induce apoptosis there in. Another killing mechanism is via the fas ligand that binds to death 
inducing receptor CD95 activating the caspase system resulting in subsequent apoptosis. The 
CD8 T-cells also secrete IFNγ and TNFα that are crucial in creating an inflammatory state 
enabling effective clearance of the respective viral pathogens [43]. 
The naïve/ precursor CD8 T-cells are defined by expression of CCR7, CD62L and CD45RA 
CD8 T-cells are constantly circulating between blood and lymph nodes surveying APCs to 
find their cognate antigen peptide MHC class I. Upon sufficient activation and CD4 T-cell 
help, CD8 T-cells are able to generate long-lived memory responses [44] via clonal 
expansion. Central memory T-cells, characterized by expression of CCR7+ and the loss of 
CD45RA- are generated, which have increased sensitivity to antigen stimulation and are 
often independent of co-stimulation. These cells produce IL-2 and proliferate into effector 
CD8 T-cells (CCR7-CD45RA-) that migrate out of the secondary lymph nodes in search of 
their cognate antigens. Upon encounter with their target(s), they produce IFNγ and TNFα in 
addition to perforin and granzyme production. This expansion/effector phase is followed by 
phase of contraction wherein 95% of these effector CD8s undergo cell death barring a few 
resulting in early memory formation. The terminal effector cells (CCR7-CD45RA+) have 
abundant cytoplasmic granzyme and perforin for immediate deployment upon secondary 
antigen encounter. This heterogeneity seems to differ according to the source of antigenic 
stimulus and the pathogen encountered, for instance in some studies CMV specific CD8 T-
cells were entirely defined to reside in the terminally differentiated effector compartment, 
whereas in an human immunodeficiency virus (HIV) setting, antigen-specific T-cells were 
found in the effector memory T-cell subset probably due to interaction of CD27 on T-cells 
with CD70 on APCs promoting an effector phenotype to compensate for limited CD4 T-cell 
help [45]. In contrast, antigen – specific T-cells have been found to reside in the 
naïve/precursor compartment in melanoma patients, yet these T-cells could not sufficiently 
produce cytokines [46]. 
1.3.2 Humoral immune responses 
The hallmarks of humoral responses are antibody mediated and orchestrated by B-
lymphocytes. The humoral response serves to neutralize extracellular pathogens and their 
toxins. Antibodies may also target non-protein antigens such as polysaccharides and lipids. 
The B-lymphocytes produce antibodies of 4 major classes upon activation with their cognate 
targets i.e. IgD, IgM, IgA and IgG. Each class of antibodies performs highly specialized 
functions to neutralize extracellular pathogens as discussed further.  
1.3.2.1 B-Lymphocytes 
Naïve B-cells are generated in the fetal liver, bone marrow, and adult bone marrow [47, 48]. 
These B-cells express membrane-bound immunoglobulins IgM and IgD, they are often 
activated in the lymph nodes, spleen and mucosal surfaces where antigens are concentrated. 
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In lymph nodes, macrophages take the captured antigens to the B-cell rich follicles and 
marginal zones wherein the antigens are displayed. Membrane bound Ig of the B-cells 
engages with displayed antigens subsequently triggering the B-cell receptor signaling. The 
activating antigens can be divided into two groups on the basis of T-cell help requirement i.e. 
T-cell dependent antigens (TD) or T-cell independent (TI). TD antigens are those that after 
binding to surface Ig of the B-cells are internalized and processed through the MHC class II 
pathway. The MHC class II-peptide antigen complex is recognized by activated CD4 T 
helper cells via its TCR along with the engagement of co-stimulatory receptors CD40 on B-
cells with CD40L on T-cells. This is called the linked recognition, the epitope recognized by 
CD4 T-cells is linked to the epitope recognized by the B-cell surface Ig [49]. This stimulates 
and provides IL-4 cytokine signals to B-cells for isotype switching and affinity maturation. 
These B-cells are referred to as follicular B-cells and make the bulk of antibodies to TD 
antigens and give rise to long-lived plasma cells capable of producing IgG, IgA and IgE. The 
TI antigens are generally non-protein structures such as polysaccharides and lipids, often 
stimulate B-cells by cross-linking the Ig receptors; they are independent of T -cell help. The 
marginal zones B-cells in the splenic white pulp are the main responders to the blood derived 
polysaccharide antigens whereas the B-1 cells respond to other non-protein and lipid 
antigens. Both these subsets produce IgM class of immunoglobulin and often do not yield 
long-lived  immune memory [50]. 
1.3.2.2 Immunoglobulins 
An antibody is composed of four polypeptide chains; 2 heavy (H) and 2 light chains (L), each 
containing a variable and constant region highly homologous to antigen receptors in T-
lymphocytes. The two mechanisms by which immunoglobulins enhance their response are (i) 
isotype switching –production of antibodies with same specificities but different isotype 
leading to varied effector functions (ii) affinity maturation –repeated stimulation with protein 
antigens leads to production of antibodies with increased affinity for that antigen. As 
described the four different classes of immunoglobulins are discussed below. 
IgM Immunoglobulins –These are the first immunoglobulins expressed on B-cells in 
monomeric form, on activation and maturation by antigenic stimulus, these B-cells secrete 
multimeric IgM antibodies (generally pentameric). Secreted IgM constitutes about 10% of all 
serum immunoglobulins. The IgM antibodies are associated with primary response and tend 
to be more polyreactive as compared to other isotypes, due to reduced affinity maturation; 
IgM antibodies have also been described to facilitate the removal of apoptotic cells [51]. 
IgD Immunoglobulins – Secreted IgD is a monomer and constitutes just 0.25 % of all the 
serum immunoglobulins with a half-life of 2.8 days, the secreted IgD has been described to 
bind unspecifically to many bacteria through the Fc region; its role in the humoral response is 
not yet clear. The IgD immunoglobulin is also present on the surface of B-cells where it is co-
expressed with IgM, IgD has been described to be involved in B-cell receptor signaling and 
in regulation of B-cell activation states [52]. 
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IgG Immunoglobulins- these are the predominant isotypes upto 75 % of all the 
immunoglobulins found in the body with longest serum half-life of upto 23 days. The 
monomeric IgG are subdivided into four different classes based on their structural and 
functional differences in the constant regions of the heavy chain (figure 1). The serum 
concentrations are in the order of IgG1 > IgG2 > IgG3 > IgG4 in healthy individuals [53]. 
IgG1, IgG2 and IgG3 can fix complement 
in the order of IgG3 >IgG1 >IgG2 and 
can mark pathogens for phagocytosis 
known as opsonization. IgG1 is crucial in 
secondary response; IgG2 and IgG3 
neutralize virus and toxins. IgG4 is the 
only sub-class that does not fix 
complement. Their affinities to FcγR (I, II 
and III) also differ; IgG1 and IgG3 bind 
to all the three classes, IgG4 binds to II 
and III, IgG2 binds only to II. Taken 
together IgG antibodies have the 
following functions (i) neutralization of 
microbes and toxins (ii) opsonization (iii) 
activation of the classical complement 
pathway (iv) ADCC mediated by NK 
cells (v) neonatal immunity (vi) feedback 
inhibition of B-cell activation. 
IgA Immunoglobulins- IgA antibodies exist in either dimeric or monomeric forms and are 
predominantly present on mucosal surfaces (sIgA), in secretions such as saliva and in breast 
milk. They are also present as monomers in serum constituting 15% of total 
immunoglobulins. The IgA are subdivided into two classes IgA1 and IgA2 based on their 
structural differences, IgA1 makes up 90% of the serum IgA and IgA2 is present at mucosal 
surfaces. The sIgA are critical in responses against viruses and bacteria at mucosal surfaces 
by means of direct neutralization. Furthermore, intracellular IgA has been described and 
could reduce microbial pathogenesis. Neutrophils express IgA receptor and maybe activated 
to perform ADCC, IgA may act as an immunopotentiator e.g. by limiting the activation of 
dendritic cells and promoting the local homeostasis in the gastrointestinal tract [53]. 
IgE Immunoglobulins- IgE is a monomeric antibody that constitutes less than > 0.01 % of 
serum immunoglobulins, It has the shortest half-life. IgE is characterized by its potency to 
induce type I hypersensitivity and allergic reactions. Furthermore it’s a critical player in the 
response against parasitic helminths. IgE binds to FcεRI that is expressed on mast cells, 
basophils and esoinophils with very high affinity leading to activation of these cell subsets 
[54]. 
 
Figure 1: A secreted Immunoglobulin g (IgG) molecule 
illustrating the heavy and light chains and the antigen binding 
site on the fab region (adapted from Basic Immunology, 4th 
edition by Abul K Abbas, Andrew H Lichtman and Shiv 
Pillai). 
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1.4 Influenza virus 
1.4.1 Influenza biology and pathogenesis 
Influenza viruses are enveloped negative strand RNA viruses that belong to the family 
Orthomyxoviridae. The characteristic features are the segmented genome containing seven to 
eight segments [55]. The influenza viruses are spherical particles with a host-derived lipid bi 
layer embedded with the surface immunogenicity defining proteins hemagglutinin 
neuraminidase and M2 protein, followed by inner Matrix 1 layer in which the eight strands of 
negative RNA are present held together by ribonucleoprotein RNP (containing the PB1, PB2 
and PA)(figure 2) [56]. 
The hemagglutinin (HA) homotrimer is the major antigenic surface protein that is cleaved 
into HA1 and HA2 subunits by the host derived proteases and is mandatory for fusion of the 
virion and the host cell sialic acid 
receptors [57, 58]. The RNA 
segment 4 encodes the HA protein, 
due to faulty RNA polymerase 
activity the HA protein is subject to 
high number of mutations and is 
driven also in part by immune 
selection pressures, resulting in 
many different subtypes (at least 18 
have been described)[59].  
The neuraminidase (NA) is encoded 
by the RNA segment 6 and is 
another major antigenic surface 
protein, the NA is crucial in 
cleaving the terminal sialic acid 
from glycoprotein and glycolipids to permit the exit of newly synthesized viral particles from 
host cells [60]. Likewise NA is subject to high number of mutations and many subtypes 
ranging from N1 through N11 have been described [59].  
The matrix 1 (M1) and matrix 2 (M2) proteins are encoded by RNA segment 7, M1 protein 
forms a sheath around the nucleoprotein complex and is present in abundance in cytoplasm 
and nuclei of the infected host cells [61]. The M2 protein is a membrane protein and signals 
for transport to cell surface of the host cell [62]. 
PB1 and PB2 polymerases are encoded by RNA segment 2 and 1 respectively. The PB2 
polymerase function is in the initiation of viral mRNA transcription and it recognizes the 5’ 
capI structures of host cell mRNAs to be used as primers. The PB1 polymerase functions by 
elongating the primed nascent mRNA. The polymerase PA is the product of RNA segment 3, 
it functions by unwinding the helix. The non-structural proteins NS1 and NS2 are encoded by 
Figure 2: A graphical representation in 3D showing the 
surface and internal proteins of influenza A virion (adapted 
from http://www.cdc.gov/h1n1flu/images.htm). 
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RNA segment 8 and functions in the export of viral RNPs to the nucleus of the host cell [63] 
and in some reports the NS1 can also function as Interferon antagonist [64]. 
1.4.2 History and epidemiology 
Influenza viruses, often referred to as the flu, are the causative agents of respiratory 
infections. Influenza virus has caused many pandemics with regular intervals and has been 
mentioned historically as early as 412 BC [65]. Richard E. Shope at the Rockefeller institute 
first identified the influenza virus in early 1930s, much later than the devastating pandemic of 
1918 [66, 67]. Influenza virus was first isolated from humans in 1933 by Christopher 
Andrewes, Wilson Smith and Patrick Laidlaw [68]. Shope also showed that sera from 
individuals who experienced the 1918 H1N1 infection could neutralize the swine virus [69]. 
The well-characterized influenza virus types are the A, B and C viruses that can be readily 
distinguished from each other by genetic testing but appear similar in manifestation of 
symptoms. The human influenza A and B viruses are responsible for yearly seasonal 
epidemics unlike the influenza C virus that causes sporadic cases [70].The influenza A 
viruses are defined into subtypes based on their hemagglutinin and neuraminidase variants 
e.g. H1N1, H3N2 and H5N1, and most of these subtypes circulate in birds and swine. There 
are no subtypes of influenza B circulating in animals, as humans are the only hosts [56, 59]. 
Influenza A viruses are very susceptible to mutations resulting in antigen drifts, and after 
accumulation of these mutations, reassortments between subtypes an antigenic shift can 
occur, where in a previously immune individuals become susceptible to a symptomatic 
disease. [24]. A wide range of influenza subtypes are endemic to pigs and birds, occasionally 
causing severe zoonotic infections in humans and consequently, adapting to new host species 
[25]. Reassortment is process by which an influenza subtype can adapt to a new host due to 
exchange of RNA segments; for e.g. It is described to occur when an avian influenza subtype 
such as H5N1, human influenza subtype such as H3N2 and swine influenza H1N1 infect a 
Figure 3: Emergence of Spanish pandemic 1918 H1N1 influenza viruses by the transmission of avian influenza 
virus to humans, the 1957 H2N2 was resultant of introduction of avian influenza RNA segments into human 
population, similarly the 1968 H3N2 pandemic was a result of avian H3 HA and PB into human population. 
(adapted from Neumann et al. 2009). 
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common host i.e. pigs that have the receptors to bind all the three subtypes. Thereby, triple 
reassortments can occur with the three subtypes, while packaging their RNA segments. This 
is linked to pandemic spread of flu infections[71]. 
Perhaps the 1918-19 H1N1 pandemic was the worst in terms of mortality with some reports 
putting the death toll at 50 million around the world [72].The two other pandemic outbreaks 
in the 20
th
 century were Asian influenza H2N2 of 1957 with a mortality of 70,000 and the 
Hong Kong influenza H3N2 outbreak of 1968 resulting in a lower disease burden since 
influenza vaccination had been introduced [73-75]. There were smaller contained outbreaks 
of 1943 and 1947 among US military personnel and the failure of vaccine that was supposed 
to prevent the 1943 H1N1 [76] (figure 3). This was followed by a milder Russian outbreak of 
1977 of an H1N1 subtype [77]. In 1997 the highly pathogenic H5N1 subtype struck with six 
fatalities and 18 infections, but it was controlled rapidly by extensive culling of live birds 
[75].  
The first large outbreak of the 21
st
 century started in the Mexican town of La Gloria, 
Veracruz in mid-February of 2009 [78]. This strain was characterized as swine-origin 
influenza H1N1 and by May of 2009, 41 countries reported fatalities. Subsequently, the 
WHO declared this wave a pandemic. In general, the infections were mild and did not require 
hospitalization [79] but severe cases were reported in pregnant women and 
immunocompromised individuals. This novel pandemic H1N1 shared a very limited 
repertoire of cytotoxic and humoral epitopes with its generic seasonal counterparts [80] 
resulting in substantial illness among children and young adults [81]. The estimated global 
mortality was 201,200 respiratory deaths and 83,300 cardiovascular deaths, 80% of the 
respiratory deaths occurred in younger people and predominantly in Southeast Asia and 
Africa [82].  
However, also in the non-pandemic years influenza viruses circulate widely in the population 
with changes in the antigenic composition called “antigenic drift”. The accumulation of 
mutations in the hemagglutinin epitopes recognized by neutralizing antibodies results in this 
phenomenon. Influenza virus adjusts its receptor binding avidity in response to immune 
pressures by altering simultaneously many amino acids on its globular head [83]. Therefore 
yearly, influenza viruses are responsible for more than 30,000 deaths and 200,000 
hospitalizations yearly in the United States alone [84]. 
1.4.3 Clinical symptoms 
Influenza transmissions may occur through respiratory droplets and often requires close 
contact or when in contact with contaminated surfaces, the average incubation period of 
influenza is 2 days following which symptoms develop within 5 to 7 days. Transmission can 
also happen through hand-to-hand contact between individuals. Common symptoms are 
fever, myalgia (muscle pain), headache, cough, rhinitis, sore throat, and gastro-intestinal 
symptoms in some cases. An uncomplicated influenza usually resolves within 7 days, but 
secondary infections such bacterial pneumonia can occur. In immunosuppressed individuals 
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such as those with HIV infection and in stem cell transplant recipients, the clinical 
manifestations can be severe and result in mortality. Influenza can be fatal in young children, 
pregnant women mainly in the third trimester and the elderly (>64 years)[85].In some very 
rare cases neurological manifestations may occur such as Guillain-Barre syndrome [86]. In 
the recent pandemic H1N1 influenza wave the most common clinical manifestations among 
426 patients in China were fever (67.4) and cough (69.5%), lymphopenia also occurred in 
68.1 % of adults and 92.3% of children, the fever duration was generally 3 days [87]. In 
another report among 642 patients in the United States the most common symptoms were 
fever (94%) cough (92%) sore throat (66%), diarrhea and/or vomiting (25%) [79]. 
1.4.4 Laboratory diagnosis 
The clinical diagnosis commonly called “influenza like illness” is generally accurate during 
the influenza season if the subjects appear with cough and/or fever with a predictive value of 
75- 80% as reported in several studies [88-91]. 
The laboratory diagnosis can be established by four different assays; virus culture, serological 
diagnosis, detection of influenza antigens, and viral nucleic acid detection by polymerase 
chain reaction (PCR). Virus culture using Madin-Darby canine kidney (MDCK) cells or 
primary rhesus monkey kidney cells (PMK) are considered the gold standard [92, 93] with 
the main readout being the cytopathic effect and additional confirmation by monoclonal 
antibodies to surface viral antigens if available, this is particularly important for 
characterizing new subtypes at the start of an influenza epidemic. Although considered to be 
very high sensitive the disadvantage is that results are available in 4-5 days. Therefore, this 
technique is no longer used in routine patient care and has been replaced by more rapid tests. 
Direct fluorescent staining assay of influenza surface antigen (DFA) in the nasopharyngeal 
aspirate is reliable and generally the results are offered on the same day, though sensitivities 
are variable ranging from 40% to 100% depending on the handling of specimens, the 
experience of the technician, and the staining procedures [94-97]. Rapid enzyme optical 
immunoassays or NA (neuraminidase) enzymatic assays have also been used. Implementing 
rapid influenza diagnostic tests (RIDTs) based on antigen detection is controversial due to the 
lack of sensitivity [98, 99]. Negative results of RIDTs must be independently established by a 
PCR based laboratory diagnosis in the immunocompromised patient group. 
The polymerase chain reaction has simplified diagnostic testing in many viral diseases, and 
influenza testing has benefited immensely. Through the use of a multiplex panel of primers 
and RT-PCR (reverse transcriptase PCR), many influenza subtypes as well as other 
respiratory viruses can be diagnosed in a single run [100]. These tests have proven to be very 
sensitive and were employed during the recent H1N1 pandemic of 2009 [101, 102] with a 
turnaround time in hours. Serological diagnoses are generally retrospectively performed, with 
detection of influenza hemagglutinin specific IgG antibodies. A four-fold rise in serum titer 
between acute and convalescent sera is considered positive. There are different techniques for 
serological diagnosis such as hemagglutinin inhibition, virus neutralization followed by 
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enzyme immunoassay to detect internal viral nucleoproteins, pseudotype viral particle 
neutralization in lieu of highly pathogenic viruses such as H5N1, single radial hemolysis to 
detect complement-mediated lysis, and ELISA (enzyme linked immunosorbent assay) to 
purified influenza antigenic proteins [103]. Serological methods are not recommended in the 
diagnosis of acute infection, since serum antibodies are induced 4-5 days post exposure or 
occurrence of symptoms and requirement of paired serum samples is a necessity to make a 
conclusive diagnosis [103]. 
1.5 Innate immune responses to influenza 
The initial host response to influenza is the formation of physical barriers such as mucins and 
collectins [104]. The innate immune response is triggered by PRRs, like TLR7/3, RIG-1 and 
NOD like (NLRP3) receptors, which promote the production of IFNα/β and IL-1β by 
respiratory epithelial cells [105-107]. However, the influenza virus has developed a 
mechanism of evasion by NS1 protein that acts as an antagonist of IFNα/β and is likely to 
delay an effective response [64, 108]. Nevertheless, the flu virus activates neutrophils and 
natural killer cells during the early phase of the infection.   
Influenza infected cells are destroyed if NK cells recognize reduced expression of MHC class 
I, in conjunction with the NK cell NKp46 receptor that has been described to interact with 
influenza hemagglutinin [109, 110]. In addition, NK cells with their CD16 (FcγRIII) can bind 
to the Fc portion of influenza bound IgG and effectively induce ADCC of infected cells 
[111]. The innate immune responses at this stage serve to limit influenza viral replication and 
promote adaptive immune responses by upregulation of MHC machinery and co-stimulatory 
molecules on accessory cells.  
Alveolar macrophages are recruited to the site of infection by epithelial cells via the 
production of CCL2 [112], upon activation, alveolar macrophages produce IL-6, IL-12 and 
TNFα creating a pro-inflammatory cytokine milieu [113, 114]. These alveolar macrophages 
have a very critical role in limiting the spread of new infections by phagocytosing the 
infected cells [115-117]. The depletion of alveolar macrophages also results in impaired 
cytotoxic CD8 T-cells and reduced antibody titers [117].  
The DCs during an influenza infection acquire antigens via two pathways:  (i) DCs 
themselves can be infected with the influenza virus [118, 119] and subsequently the viral 
antigens are processed by a MHC class I pathway and presented to cytotoxic lymphocytes, 
(ii) the second route of influenza antigen accrual is by active phagocytosis of virus particles 
and infected epithelial cells, followed by degradation and processing of viral protein antigens 
via the MHC II pathway and subsequent antigen presentation to CD4 T helper cells, A 
mechanism described previously as cross presentation  can occur activating CD8 T-cells in 
parallel [120, 121].  
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1.6 T-cell mediated immune responses to influenza 
Influenza virus infection generates a range of effector CD4 and CD8 T-cell responses. These 
have been found to be critical in regulating an effective anti-flu response, reducing 
symptomatic infections and are crucial in protection in the course of a second encounter with 
influenza. Flu-induced activation of CD4 and CD8 T-cells is responsible in generation of 
heterosubtypic immunity i.e. protection against infection with new subtype of influenza due 
to encounters with previous pathogens showing related subtype [122]. 
1.6.1 CD4 T-Lymphocytes in response to influenza 
CD4 T-cells are activated after recognizing influenza antigenic peptides in conjunction with 
MHC class II on the surface of dendritic cells. Activation of CD4 T-cells is often based on 
the strength of the stimulation and the cytokine micro-environment that lead them to   
differentiate into T-helper subsets [123]. Th2 differentiated cells are responsible for activation 
and production of antibodies from B-cells, mainly through production of IL-4, IL-5 and IL-13 
[40, 124]; yet other reports differed in the beneficial role of Th2 type cells [125] suggesting  
that Th1 responses inhibit a Th2 response during an influenza infection [126]. Th2 cells 
provide signals for antibody isotype switching and affinity maturation of influenza specific 
antibodies, T-cell clones specific for internal flu proteins were equally efficient in inducing 
hemagglutinin specific B-cell responses as compared to hemagglutinin specific T-cell clones 
[127]. 
Th1 responses to influenza are characterized by the production of IFNγ and IL-2 that results 
in the activation of macrophages and CD8 T-cells [127, 128]. In addition, long-lived memory 
CD8 T-cells can be generated with help from Th1 subsets [129]. Memory CD4 Th1 type cells 
in the lungs can enhance the quality of innate immune inflammatory cytokines and 
chemokines independent of IFNγ and TNFα [130]. Lung resident memory CD4 T-cells have 
been described, that can quickly respond to the second encounter with the nominal pathogen 
[131]. Pre-existing CD4 T-cells specific for pandemic influenza 2009 showed cytotoxic 
potential and were responsible for decreased illness and disease severity in the absence of 
neutralizing antibodies [132]. The CD4 T-cells that migrate to lung during an influenza 
infection are characterized by an effector phenotype having reduced expression of CCR7 and 
CD62L, stable expression of CD44 and CD49d and low expression of CCR5 and CD25; 
these cells produced copious amounts of IFNγ [133]. Heterosubtypic immunity is a very 
important mechanism by which memory CD4 T-cells can mediate protection: healthy 
volunteers could also generate potent anti-pandemic influenza responses when vaccinated 
with the generic seasonal influenza vaccine [134]. Memory T-cells specific for H3N2 
influenza were also able to cross-react with H5N1 subtype in healthy individuals [135]. 
1.6.2 CD8 T-Lymphocytes in response to influenza 
CD8 T-cells are activated by influenza antigenic peptides on MHC class I molecules on 
APCs in the lymph nodes, followed by their differentiation into cytotoxic CD8 T-cells 
(CTLs) and migration to the sites of infection. CD8 T-cells may subsequently eliminate 
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infected cells and prevent further production of viral progeny [136]. These cytotoxic CD8 T-
cells show a very high specificity to the internal conserved proteins of Influenza such as M1, 
NP including PB1 and PA, that maybe central to the heterosubtypic protection against 
influenza A viruses [137-139]. Heterosubtypic CTL response to the newly identified 
influenza A virus H7N9 subtype was also described, induced from exposure to seasonal 
H3N2, H1N1 and pandemic H1N1 2009 [140, 141]. In addition, large numbers of cross-
reactive CTL epitopes were conserved in the pandemic 2009 strain blunting disease severity 
[80]. 
The specific CTLs lytic activity is mediated via two pathways i.e. either by releasing perforin 
and granzymes that cleave essential components of infected cellular machinery necessary for 
viral replication [142, 143] or by the induction of apoptosis in influenza infected cells via the 
fas ligand interaction with the death inducing receptor CD95 (activating the caspase system in 
the infected cells) [144]. The cytokine production is skewed towards pro-inflammatory 
molecules, characterized by abundant production of TNFα and IFNγ [145]. An influenza 
infection or vaccination creates a pool of long-lived influenza specific CTLs that are mainly 
located in the central and effector memory T-cell pool. These immune cells can be quickly 
recruited upon re-encounter with the nominal targets without the need of dividing into 
daughter cells [146-148]. A Prospective study, conducted during the pandemic influenza has 
also emphasized the importance of terminal effector memory CTLs specific to the conserved 
M1 peptide epitope, these CTLs were the most significant correlate of immune protection 
against pandemic influenza [149]. 
1.7 Humoral immune responses to influenza 
Influenza infection or vaccination generates influenza directed antibodies produced by 
activated B-cells [150]. The antibodies induced by the influenza hemagglutinin primarily 
correlate with immune protection, in particular they can prevent viral attachment to host cells 
and block receptor mediated endocytosis [151]. The sterilizing immunity resultant of 
antibodies targeting the trimeric hemagglutinin complex is strain-dependent and often fails to 
neutralize intrasubtypic drift strains or other subtypes [152]. This is particularly evident 
following the H1N1 pandemic influenza 2009 wave, where individuals, born before 1950, 
were relatively sparred from symptomatic infection [153-155]. 
Antibodies have been described to neuraminidase (NA) protein, which is pivotal to the 
release of newly formed virions. Antibodies directed to NA do not neutralize the virus but 
limit the spread of infection [156, 157]. In addition, antibodies to the transmembrane M2 
protein have also been characterized. M2 protein unpacks the virus after the receptor-
mediated endocytosis. Since the M2 protein is relatively well conserved, it may also 
contribute to heterosubtypic immune responses [158-160]. Antibodies against the viral 
nucleoproteins (RNP) that are highly conserved have also been described and could also be 
important in contributing to heterosubtypic immunity [161]. The non-neutralizing antibodies 
induced against NA, M2 and viral nucleoproteins could further contribute to protective 
immunity by the mechanism of ADCC [162]. However other reports suggest that high titers 
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of low avidity non-neutralizing antibodies maybe detrimental and are associated with poorer 
outcome [163]. Other studies have described the importance of the classically activated 
complement pathway in individuals with C1q genetic polymorphisms, these individuals had 
poorer clinical outcomes and developed pneumonia after the recent pandemic influenza 
infection [164]. 
IgM, IgA and IgG isotype of antibodies can be generated by the primary infection. IgM is not 
produced upon a secondary infection [165]. Other studies have suggested the importance of 
IgM and its role in activation of complement C3, which is crucial in maintenance of long-
lived memory B-cell responses [166]. The presence of Influenza nucleoprotein specific serum 
IgA has also been correlated with a recent onset of influenza infection [167]. Mucosal sIgA 
(secretory), produced by resident B-cells that accumulate in lung following infection, were 
described to be important for reduced disease severity and protection [168-170]. 
1.8 Influenza vaccination systems and prevention  
The major causative agents of epidemics and pandemics resulting often in severe cases are 
influenza A virus subtypes followed by the influenza B. while the influenza C subtype is of 
limited concern. Therefore, all vaccine formulations contain Influenza A and Influenza B 
antigens. The antigenic drift to which both influenza A and B subtypes are susceptible 
mandates the change in antigen formulations every year based on epidemiological 
surveillance. To successfully induce protection, the vaccine antigen strain must have at least 
85% consensus with those strains that are currently in circulation [171]. Since different 
influenza A subtypes have resulted in epidemics and pandemics, the current vaccine 
formulations are often trivalent inactivated vaccines (TIV) i.e. two different subtypes 
generally a H1N1 and H3N2 from influenza A and an influenza B strain are included or 
quadrivalent where two antigenically (B/Yamagata and B/Victoria) different B strains are 
included [172-174]. 
The currently licensed influenza vaccines fall into two broad categories inactivated and live 
virus vaccines. Inactivated vaccines are composed of whole inactivated virus or split virus 
containing purified surface antigens. The inactivated vaccines are available in three formats 
i.e inactivated whole virus, split and sub-unit vaccines. The live viruses are grown in chicken 
eggs or cells, and thereafter formaldehyde inactivated, purified, and concentrated to 15μg 
doses of Hemagglutinin [175], the split vaccines are additionally detergent treated to 
dissociate the viral envelope proteins [176], the subunit vaccines are put through further 
purification steps [177], further the split and subunit vaccines have comparable 
immunogenicity relative to the whole virus inactivated vaccine.  
The TIV vaccines are generally administered intramuscularly and induce predominantly 
serum IgG responses against strain specific hemagglutinins and neuraminidases [178]. Since 
the TIV are relatively little immunogenic, they might be coupled with adjuvant systems to 
enhance the influenza specific immune response. In times of pandemics, when the demand 
for protective vaccines is high, the adjuvants can greatly decrease the concentration of the 
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purified antigen. The licensed adjuvants in use are alum salts, oil in water emulsions such as 
MF59 (Novartis), ASO3 (GSK Biologicals), and virosomes. The oil in water emulsion 
adjuvanted vaccines were superior in immunogenicity when compared to non-adjuvanted 
vaccines tested during the pandemic 2009 [179, 180]. However, following the AS03 
adjuvanted vaccination campaign several European countries reported increased incidence of 
narcolepsy cases [181]. The virosomal adjuvanted vaccine or the virus like particles (VLP) 
are composed of phospholipids and phosphatidylcholine, complexed with influenza envelope 
glycoproteins hemagglutinin and neuraminidase [182]. The virosomal vaccine has been tested 
in adults, the elderly, and in immunocompromised patients with good immunogenicity [183]. 
The live attenuated virus vaccines (LAIV) were based on the concept of mimicking a course 
of natural flu infection, and were hypothesized to induce both humoral and cellular immune 
responses; they were developed by passaging the virus in suboptimal conditions resulting in 
attenuation. These attenuated virus strains are temperature sensitive and adapted to grow at 
25°C, which is the temperature of the nasal passage, but not adapted to grow at 35°C, the 
temperature of the lower respiratory tract [184]. The LAIV vaccines are administered 
intranasally and are described to induce a longer lasting humoral response and are especially 
effective in children [185]. These LAIV are not recommended in immunosuppressed patient 
groups such as aHSCT recipients and HIV infected individuals. 
Antiviral agents with effect against influenza include amantadine/rimantadine, oseltamivir, 
and zanamivir [186]. The amantadines were used before the development of neuraminidase 
inhibitors; these inhibit viral uncoating by blocking the proton channel activity. The 
limitations include limited effectiveness against influenza B viruses and rapid development of 
resistance [187] and these drugs are today used very rarely. The second class of drugs blocks 
the active site of neuraminidase on infected host cells thereby preventing the release of virus 
and includes sialic acid analogues such as oseltamivir (oral) and zanamivir (inhalation) [188]. 
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1.9 Allogeneic hematopoietic stem cell transplantation (aHSCT) 
Allogeneic HSCT is used primarily for treatment of hematologic malignancies, non-
malignant and congenital diseases. For non-malignant diseases the aim is to replace the 
abnormal hematopoietic compartment with healthy donor stem cells or to provide factors 
lacking in patients with enzyme defects. [189]. For treatment of malignancies, the recipient is 
conditioned using two broadly classified types of regimens (i) myeloablative regimens that 
eliminate malignant cancer cells and induce general immunosuppression allowing 
engraftment (ii) reduced intensity regimens that is mainly immunosuppressive and relies on 
the graft to perform eradication of malignant cancer cells called the graft-versus-leukemia 
effect (GVL) [190]. The donor hematopoietic stem cells are characterized by expression of 
the CD34 antigen and can be from different sources i.e. bone marrow cells, cord blood cells, 
or peripheral blood stem cells; the latter mobilized from the donors using granulocyte colony 
stimulating factor (G-CSF) and sometimes depleted of T -lymphocytes. The donors are 
usually HLA-identical siblings or unrelated registry donors. Early on mostly well HLA 
matched donors were used but in recent years, better prevention strategies against graft-vs-
host disease (GVHD) allow the use of, mismatched, or haploidentical donors [190]. 
GVHD results from immunological attack by the allogenic graft primarily mediated by donor 
T-cells on the tissues and organs of the recipient. The severity and outcome of GVHD are 
dependent on recipient age, stem cell source and conditioning regimens. GVHD within the 
first 100 days post transplantation is commonly referred to as acute GVHD (aGVHD) and is 
predominantly mediated by T-cells in response to donor cell-surfaces and secreted factors due 
to the conditioning regimens. The aGVHD pathogenesis consists of three stages (i) initiation 
phase – the MHC disparities and danger signals (PAMPs and DAMPs) are the triggers which 
activate host innate immune cells and APCs to present antigens activating T-cells, (ii) effector 
phase – T-lymphocytes activated by APCs home to secondary lymphoid organs and 
proliferate creating an inflammatory cytokine milieu, (iii) treatment phase – where the main 
prophylaxis is topical steroids and methylprednisone. The primary target organs are the skin, 
gastrointestinal tract and liver, with aGVHD being divided into 4 grades based on the severity 
of symptoms [191, 192]. 
Chronic GVHD (cGVHD) has a different clinical presentation and usually develops after the 
first 100 days post transplantation; its symptoms are frequently similar to those caused by 
autoimmune diseases. It is predominantly mediated by CD4 T-cells polarized into Th2 cells 
that produce IL-4, IL-5 and IL-11. These Th2 cells are described to be the resultant of faulty 
negative selection due to thymic damage caused by conditioning regimens. The Th2 
cytokines activate the production of fibrogenic cytokines (IL-2, IL-10, TGFβ1), which further 
activates macrophages to produce platelet-derived growth factor (PDGF) and TGFβ1. These 
factors promote proliferation of tissue fibroblasts. Further there is dysregulation of B cell 
activation due to presence of BAFF (B-cell activating factor), all these mechanisms 
contribute to a systemic autoimmune-like syndrome and predominantly present as symptoms 
in oral, mucosal, skin, kidneys, lungs, liver and gut tissues [192]. Consequently, chronic 
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GVHD is major complication limiting the success of HSCT with a 13% fatality rate among 
recipients [193]. 
1.10 Immune reconstitution following HSCT 
Early after transplantation the susceptibility to infections is pronounced due to strongly 
suppressed marrow function with very low circulating granulocytes (figure 4). The 
granulocyte recovery is within 12-14 days with peripheral blood stem cells and a few days 
later if bone marrow is used. Monocytes recover within a month but may not be functionally 
competent for over a year [194], dendritic precursors recover within 6 months and in 
particular the follicular dendritic cells recover at a relatively slow pace resulting in delayed 
function of germinal centers and memory B-cells [195]. The NK cells recover rapidly post 
transplantation reaching optimal levels within a month [196]. 
The B cell recovery is slow over a period of 1-2 years, though relatively faster rates have 
been observed after PBSC grafts In addition the B cell recovery is dependent on GVHD 
and/or its treatment [197-199]. In the process of recovery, the predominant phenotype of B-
cells was CD9c, CD38, IgM, and IgD [200]. The immunoglobulin gene usage was skewed 
towards regions that are seen in neonatal B-cells. The serum immunoglobulins recover in the 
order of IgM, IgG1 and IgG3, followed much later by IgG2, IgG4 and IgA. These early 
isotypes are characterized by irrelevant reactivity and consist of autoantibodies; but also may 
be specific as Wahren et al describe that anti-viral IgG was present early and persisted in 
some cases up to 12 months after transplantation [201, 202]. The specific reactivity against 
protein antigens recovers faster than reactivity against polysaccharide antigens. Other studies 
have indicated that blood stem cell grafts delayed the serum IgG reconstitution as compared 
Figure 4 – Types of infections that occur relative to time after marrow infusion or transplantation before the implementation 
of prophylaxis. Adeno-Adenovirus, CMV-cytomegalovirus, HSV-herpes simplex virus, VZV-varicella zoster virus and 
GVHD. (Adapted from 2nd edition Transplant infections / editors, Raleigh A. Bowden, Per Ljungman, Carlos V.Paya). 
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to bone marrow grafts [203]. Vaccination induced antibody responses are frequently sub-
optimal especially the first year after transplantation and repeated boosters are almost always 
needed to achieve similar protection rates as in immune competent individuals. 
The CD4 T-lymphocyte recovery is slow; the numbers are typically low over 1 to 3 month 
period, followed by gradual rise over several years [204]. There is predominantly a memory 
phenotype of CD4 T-cells characterized by expression of CD45RO, CD11a, HLA-DR and 
CD29 and to lesser extent CD45RA, CD28 and CD62L. In the absence of chronic GVHD the 
naïve CD4 T-cell numbers after a year were comparable to normal individuals [205]. The 
naïve CD4 T-cells recover at a slower pace as compared to the memory CD4 T-cells, due to 
reduced thymic function and often correlate with age, with younger patients having a faster 
recovery. PBSC grafts are relatively abundant with both naïve and memory CD4 T-cells and 
recovery is enhanced as compared to bone marrow grafts [206]. The ability to generate 
antigen specific responses when stimulated with tetanus toxoid correlated coincided with 
generation of naïve CD4 T-cells [207]. The T-cell receptor repertoire recovered faster if a 
patient received cord blood graft as compared to T-cell depleted PBSC graft [208]. 
The CD8 T-cells are suppressed for 2-3 months, Thereafter, their numbers rise rapidly 
resulting in a CD4:CD8 inversion ratio, These cells are memory CD8 T-cells characterized by 
CD45RO, CD11a, CD11b, CD29, CD57 and HLA-DR expression [209]. Some studies 
described this particular phenotype of CD8 T-cells as suppressor or anergic cells that inhibit 
cell mediated cytolysis. These CD8 T-cells have been reported to be increased in chronic 
GVHD [210, 211].  
1.11 Influenza infections and risk factors after HSCT 
Influenza infections have over the years caused significant morbidity in this particular patient 
group. During the influenza epidemic of 1991-92 in Houston, Texas, influenza A virus was 
isolated from 8/28 patients (29%) and among 6 of these HSCT patients with pneumonia, the 
mortality was 17% [212]. The incidence of influenza was 3.5% in allo-HSCT patients with 
direct influenza related mortality of 15.3 % in 37 European centers over three seasons 1997-
2000. In another retrospective study the documented influenza incidence rate over 12 seasons 
(1989-2002) in 4797 HSCT patients was 62 (1.3%), 18/62 cases developed pneumonia (29%) 
and the mortality among these was 5/18 (28%) [213]. During the first season of the pandemic 
H1N1 influenza, Ljungman et al. conducted the largest published study involving 64 HSCT 
centers with 286 patients (222 allo-HSCT and 66 auto-HSCT) of whom 125/286 (44%) were 
hospitalized, 93/286 developed lower respiratory tract infection (LRTI), 11.5% required 
ventilation support, and the mortality was 6.3% (18/286) [214]. Choi et al reported that 
pandemic influenza infection in HSCT patients manifested as severe respiratory disease with 
prolonged viral shedding relative to the seasonal influenza infections [215].  In another 
evaluation study of 37 HSCT patients, 18 were hospitalized and 6 required ventilation 
support; the mortality was 7/37 (18.9%) within 30 days of symptom onset and 11/37 (29.7%) 
within 60 days of symptom onset [216]. Similar mortality rates were observed in many 
different centers during the pandemic influenza season [217-220]. 
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The main risk factor for severe outcome (LRTI and mortality) has in several studies been 
reported to be lymphopenia as reviewed by Engelhard et al [219]. Machado et al report that 
seasonal exposure and intensive conditioning were risk factors for acquiring influenza [221]. 
In other studies use of a myeloablative conditioning regimen and autologous HSCT were 
associated with higher LRTI compared to non-myeloablative regimen [222]. Furthermore, 
chronic steroid use amounting to ≥20mg/day at onset of symptoms was associated with LRTI 
and mortality [220]. In the multicenter study by Ljungman et al., it was found that older age 
and lymphopenia were risk factors for LRTI, while influenza onset early after transplant 
during neutropenia, older age and infection with oseltamivir resistant strains were risk factors 
associated with mortality [214]. 
1.12 Influenza vaccination in HSCT recipients 
Influenza vaccination is the mainstay for the prevention of influenza in HSCT patients. Most 
studies have assessed only the antibody responses that generally are poorer than in immune 
competent individuals. In a study of 48 HSCT patients vaccinated with a seasonal trivalent 
influenza vaccination, the longer time to vaccination from transplant was a significant 
variable in eliciting protective antibody responses [223]. In a randomized study including 117 
patients, the response rates were 25-34% and the administration of GM-CSF only marginally 
improved the response [224]. Seasonal influenza vaccination early after transplant within 6 
months was ineffective as measured by HI and in some studies before 12 months after HSCT 
[223, 224]. The only study assessing clinical efficacy although not randomized, showed a 
protection of 80% in a cohort of 177 HSCT patients [221].  
During and after the pandemic influenza 2009, many centers conducted vaccination efficacy 
studies. Humoral responses were evaluated in 22 adult HSCT patients after ASO3 adjuvanted 
pandemic influenza vaccination, with seroprotection rates of 45.5 % (10/22) and after a 
second dose the rate of 73 % (16/22) [225]. Two doses of adjuvanted pandemic vaccine 
resulted in better rates of seroprotection than a single dose [225-231]. In another study the 
responses were dependent on chronic GVHD with modest 53% seroprotection as measured 
by HI. Issa et al observed that after a single dose of non-adjuvanted pandemic influenza 
vaccine in 82 HSCT patients the seroprotection rate was 51% and dependent on the timing of 
vaccination from transplant, with patients vaccinated further away from transplant having 
improved seroprotective rates [232]. 
Cellular immune responses may be better indicators of immunogenicity by the vaccines and 
possibly mediate protection against severe influenza especially in the absence of protective 
HI titers. Haining et al describe a significant increase in influenza specific CD4 T-cell 
proliferation after vaccination in five pediatric allo-HSCT patients, while there were no 
increases in influenza specific IgG [233]. Avetisyan et al. show that an influenza specific 
cellular response could be induced early within 3 months after transplantation when 
vaccinated with seroprotection rate of 29% among 14 HSCT patients [234]. Increases in IFNγ 
production and influenza specific CD8 T-cells measured by soluble MHC class I/peptide 
multimers after seasonal vaccination could be measured, although decreased as compared to 
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healthy controls in another study [234]. In a study with the pH1N1 vaccine, significantly 
improved cellular responses (p=0.008) were also seen [235]. In another study with the use of 
both TIV and ASO3 adjuvanted pH1N1 vaccine, CD4 T-cell cross-reactivity to both H1 and 
H3 antigens could be characterized in allo-HSCT patients [236]. Mariotti et al observed 
minimal increases in influenza specific CD137+ T-cells as measured at day 50 post 
vaccination among 9 allo-HSCT patients [237]. Garland et al observed in a prospective study 
that among 4 allo-HSCT patients with influenza H1N1 infection, all of them exhibited 
impaired cellular immune responses [238]. 
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2 AIMS 
The aim of this thesis was to study and improve influenza vaccination responses in aHSCT 
recipients since influenza vaccination responses are sub-optimal in aHSCT recipients. In 
order to first understand correlates of vaccination mediated immune response, a prospective 
study of over 2000 immune competent individuals was conducted during the H1N1 pandemic 
influenza season of 2009 in Sweden, following which these specific aims were formulated. 
Specific aims 
To define humoral immune profiles after a pandemic influenza infection or adjuvanted 
influenza vaccination in immune competent individuals using a high content influenza 
proteome peptide microarrays. (Paper I) 
To evaluate the benefit of pre-transplant influenza vaccination of aHSCT candidates or their 
donors on the influenza seroprotection rate in the first months after transplant. (Paper II) 
To characterize the antibody and T-cell responses to an adjuvanted virosomal influenza 
vaccine as compared to the responses to the seasonal non-adjuvanted vaccine in aHSCT 
recipients. (Paper III) 
To determine if pandemic influenza hemagglutinin specific CD8 T-cells generated during the 
course of natural pandemic influenza infections are phenotypically different as compared to 
vaccination with the adjuvanted influenza vaccine. (Paper IV) 
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Figure 5 – Principle of peptide microarray (courtesy- Davide 
Valentini) 
3 RESULTS AND DISCUSSION 
3.1 Pandemic H1N1 viral proteome peptide microarray (Paper I) 
Due to the paucity in pandemic influenza epitope data clearly linked to clinical endpoints i.e. 
epitopes linked to natural pandemic influenza infection and/or pandemrix
®
 vaccination. We 
designed a high content peptide microarray (figure 5) containing the entire proteome of 
pandemic Influenza A virus (A/California/08/2009(H1N1)) proteome and hemagglutinin 
proteins from 12 other influenza A subtypes (2304 unique features) to answer these questions 
i) what is the immune recognition pattern that segregates individuals at high risk to be 
infected with influenza, ii) what are the differences in IgG recognition patterns induced by 
vaccination versus infection, iii) and if there exist shared epitope recognition patterns 
comparing different hemagglutinin proteins from influenza A strains, including the 
hemagglutinin from the pandemic strain Influenza A virus (A/South Carolina/1/1918(H1N1). 
This was possible in the current study using the serum aliquots from a prospective study 
[239-241], where 2000 individuals were followed before and after vaccination, or H1N1 
infection, respectively. We identified 19 individuals with a positive pandemic H1N1 RNA 
Swab with a pre-infection and post-infection serum samples. These were used to assay the 
detailed Flu epitope recognition 
pattern.  Serum samples from 19 
(age and sex-matched) individuals 
vaccinated with the AS03 
adjuvanted vaccine against 
pandemic H1N1 influenza 
(Pandemrix
®
) were used as controls. 
The prospective design of the study 
allowed characterizing serum-
epitope recognition patterns before and after pandemic influenza infection and/ or 
pandemrix
®
 vaccination. Clusters of 262 epitopes were differentially recognized before the 
pandemic season i.e. before pandemic flu infection/vaccination. Following either pandemic 
flu infection or pandemrix
®
 vaccination a cluster of 250 epitopes were differentially 
recognized. 
Pre-existing pandemic influenza specific IgG before the flu season in individuals with 
previous vaccinations was observed, 10 epitopes from the pandemic strain (6 from 
polymerase PA, 2 from matrix1, 1 from polymerase PB1 and 1 epitope from hemagglutinin 
VEPGDKITFEATGNL). In contrast Only 2 epitopes from the 2009 pandemic flu strain were 
recognized in the serum from individuals who later developed a pandemic flu infection, i.e. 
polymerase PA (GRDRIMAWTVVNSIC) and neuraminidase (NFSIKQDIVGINEWS). Pre-
existing serum IgG to pandemic hemagglutinin in vaccinated individuals before the onset of 
the flu season probably due to past exposures [242-245] and previous vaccinations (the 
interviews of the study participants showed that individuals who chose to be vaccinated did 
also previously prior to 2009/2010 and vice versa [241]). Seven epitopes from flu internal 
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proteins in serum from individuals who chose to be vaccinated were recognized. These non-
neutralizing antibodies might decrease morbidity and lead to increased viral clearance 
through binding to FcRs and subsequent activation of CD8 T-cells [246-250]. Conserved 
influenza internal proteins may therefore aid to elicit memory B-cells that are long-lived [251, 
252] and contribute to heterosubtypic immunity during antigenic drifts. 
Pandemic Influenza infection generated new neuraminidase specific IgG reactivity leading to 
the recognition of the epitopes QGALLNDKHSNGTIK, NDKHSNGTIKDRSPY from 
neuraminidase [Influenza A virus (A/California/08/2009(H1N1)]. Moreover, in the absence 
of neutralizing HA antibodies, neuraminidase (NA) specific antibodies would be instrumental 
to mount protective immune responses against the pandemic virus [253]. Of note, we 
observed in serum from the current cohort an increase in NA epitope reactivity, while no 
pandemic H1 epitopes were commonly recognized. 
Differential serum IgG recognition was highly focused on hemagglutinin (H1) and was 
restricted to classical H1 antigenic sites in the serum from individuals both before and after 
pandemic infection and vaccination. The peptide epitope SRYSKKFKPEIAARP from the 
HA [Influenza A virus (A/Swine/Indiana/P12439/00 (H1N2)] was strongly recognized in 
serum from individuals both prior to and after flu infection (2.50 and 2.60 fold change 
respectively), this epitope belongs to the Ca antigenic site on the H1 and is highly 
homologous to the SRYSKKFKPEIAIRP epitope from HA [Influenza A virus 
(A/California/08/2009(H1N1)] on the HA receptor binding domain. Antibodies against swine 
influenza virus were found to neutralize pandemic flu in experimental models [69, 254], at 
present there is insufficient evidence for the beneficial role of these antibodies in humans. 
However non-neutralizing 
antibodies produced against 
the swine origin H1 - due to 
past exposures - could 
enhance virus fusion and 
promote infection [255]. 
Most significantly the 
subjects in the current study 
who experienced H1N1 
infection exhibited increased 
levels of IgG against swine 
origin 
SRYSKKFKPEIAARP. 
A novel epitope 
VEPGDKITFEATGNL on 
the antigenic site of the 
pandemic flu hemagglutinin was exclusively recognized in serum from individuals prior to 
flu season (16/19 individuals). This was also found to be true for the post-flu season period 
Figure 6 - The epitope VEPGDKITFEATGNL (highlighted in red) 
exclusively recognized in serum from individuals (n=17) who were 
vaccinated mapped on the crystal structure of the 2009 H1N1 influenza 
virus hemagglutinin receptor-binding domain (PDB ID - 3LZG) 
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(serum from 17/19 individuals). Consequently, we further mapped the epitope 
VEPGDKITFEATGNL (251-265aa) from hemagglutinin [Influenza A virus 
(A/California/08/2009(H1N1))] using the PDB entry 3LZG (figure 6) and 3MLH of the 
Crystal structure of the 2009 H1N1 influenza virus hemagglutinin receptor-binding domain 
[256]. This reactivity was completely absent from the IgG-epitope recognition repertoire of 
the flu-infected individuals prior to and after the flu season. Most likely, this epitope 
represents a dominant response associated with previous Flu vaccination. A rabbit mono-
specific antibody directed against this epitope was prepared but did not neutralize the 
pandemic flu in-vitro; functional significance of this epitope could not be established.  
Although the current study may be limited due to the fact that only IgG directed against linear 
epitopes could be characterized with conformational epitopes being missed, however a 
distinct IgG recognition pattern was identified. These patterns segregated based on H1N1 
infection and vaccination and could be clearly linked to a clinically relevant endpoint:  
pandemic influenza infection leads to a different array of epitope recognition as compared to 
the Pandemrix
®
 vaccine. 
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3.2 Evaluation of pre-transplant influenza vaccination in aHSCT (Paper II) 
Pre-transplant vaccination of the donor, the recipient, or both has been evaluated previously 
in the context of hepatitis, tetanus, polio, and pneumococcal antigens and found to positively 
influence antigen specific IgG levels in the first year after transplant [257-260]. However, this 
has not been studied previously for vaccination against influenza. Accordingly, a randomized 
prospective study was conducted from Oct 2007 to January 2010 in two Brazilian HSCT 
centers to evaluate alternative schedules of pre-transplant influenza vaccination in an aHSCT 
setting. 
122 HSCT recipients and their donors were assigned to three randomization groups: No pre-
transplant vaccination (n=38) (group1), donor pre-transplant vaccination (n=44) (group 2), or 
recipient pre-transplant vaccination (n=40) (group 3).  
Donor serum samples were taken at study admission (baseline), and around the day of HSCT. 
Recipient serum samples were taken at baseline and on days zero (dzero), +30 (d30), +60 
(d60), +100 (d100), +180 (d180) and after d180 vaccination.  Specific serum IgG was 
assessed by both hemagglutinin inhibition (HI) and, in 57 patients; by an indirect influenza-
specific ELISA at specified times after HSCT. Seroprotection was defined by the presence of 
HI Ab ≥ 1:40. Seroresponse was 
defined by ≥ 4-fold rise in HI Ab 
titers after vaccination. 
Donors belonging to the 
randomization group 2 had 
seroprotective HI Ab titers 
against H1 and H3 antigens 
compared to donors belonging to 
groups 1 and 3 (p<0.001). The 
recipient seroprotection rates at 
baseline for H1(18.5%), H3 
(33.6%) and B (64.7%) antigens. 
40 HSCT candidates assigned to 
group 3 received pre-transplant 
vaccinations at a median of 10.5 
days before transplantation. 
Seroresponse rates evaluated in 
39 patients upto day 30 were H1 
(17.9%), H3 (25.6%) and B 
(30.8%) antigens. 
During the follow-up the 
geometric titers (GMT) against H1 (p=0.028) and H3 (p<0.001) were highest in the pre-
transplant recipient vaccination group (group 3) until d.180 after transplantation (figure 7).  
Figure 7 - Dynamics of HI IgG titers up to day 180 according to 
randomization and different influenza antigens 
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Influenza specific IgG was analyzed using an indirect ELISA assay in a subgroup of 57 
patients; 17 from the group 1, 20 from the group 2, and 20 from group 3. There was a 
significant difference in the antigen specific serum IgG level against 
A/H1N1/California/2009 between the 3 study groups at 6 months (day 180) after HSCT with 
the strongest increase seen in serum from recipients vaccinated pre-transplant (group3) 
(p=0.02) (figure 8). In addition to HI, we assessed specific IgG using an indirect ELISA to 
broaden the assessment of the humoral responses, since the ELISA measures IgG against 
epitopes from the hemagglutinin, the neuraminidase, and trace amounts of the matrix 1 
protein [261-264], apart from the neutralization epitopes of HA; these other epitopes may be 
beneficial in ADCC and complement fixation. 
The influenza vaccine was administered to 63 of the 122 recipients (51.6%), at a median of 
193 (145 to 281d) days after transplantation. The seroresponse was evaluated in 59 patients; 
we could not identify any significant variables associated with seroprotective titers on day 
180.After d180 vaccination, recipient seroresponse rates were also poor when assessed by HI, 
varying from 8% (antigen B) to 20% (H1) in concordance with previous studies [225, 236, 
265, 266]. 
The primary study objective was to improve recipient seroprotection during the first months 
after transplantation; a period in which influenza vaccine is frequently ineffective [223]. The 
titer at baseline was significantly associated with protective titers to all three influenza 
antigens at d60 in accordance with previous observations that if either donor or recipient is 
immunized pre-transplant, the likelihood of 
transfer or persistence of immunity is 
increased [260, 267-269]. Although we did 
not see a significant effect of donor pre-
transplant vaccination, the pre-transplant 
influenza vaccination of the HSCT 
candidate significantly improved the 
antibody titers to H1 and H3 antigens until 
day 180. An earlier post-transplant 
vaccination would have been beneficial to 
prolong the immunity as seen in other 
studies assessing vaccination responses to 
other target antigens [270-273]. Despite the 
poor immunogenicity of the vaccine reflected by the low seroresponse and seroprotective 
rates during follow-up, the pre-transplant vaccine efficacy was higher than 65%. Future 
vaccination strategy might be to vaccinate the recipient pre-transplant and boost this response 
early within 3 months after transplantation in the recipient. Efforts should also therefore be 
made to limit the risk of influenza exposure in HSCT recipients.  
Figure 8 - Influenza specific relative serum IgG assayed by 
an indirect ELISA in a sub-group (n= 57) at day 180. 
Medians are indicated (p<0.05*).  (Recipient + group 3, 
Control- group 1, Donor + group 2). 
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3.3 Immunogenicity of virosomal adjuvanted trivalent influenza vaccination 
in aHSCT (Paper III) 
Since the seasonal subunit vaccination response is frequently sub-optimal, it is important to 
evaluate other possibly more efficient vaccination systems. The immunogenicity after a 
single dose (0.5 mL) of adjuvanted trivalent virosomal vaccination was therefore evaluated in 
a cohort of 21 HSCT recipients and compared to a control cohort of 30 HSCT recipients who 
received a single dose (0.5 mL) of non-adjuvanted seasonal trivalent subunit vaccination over 
four seasons from 2010-2014.  
Serum and blood samples were collected before and at 4 weeks after respective vaccination 
Whole blood IFNγ (gamma-interferon) release assays were tested both prior to and 30 days 
after vaccination in response to influenza pandemic (pdm) H1N1, H3N2 and B antigens. 
HLA-A*02 dextramers (GILGFVFTL Matrix 1 protein), (RLATGLRNV hemagglutinin 
(pdm 2009)) to gauge for the absolute number of antigen-specific CD8 T-cells, and pandemic 
2009 hemagglutinin inhibition (HI) assays, to test for neutralizing antibodies, were used as 
immunological readouts. 
The hemagglutinin inhibition (HI) titer responses to pandemic H1 were poor in both cohorts, 
with only 13.3 % (4/30) after the seasonal vaccination and 23% (5/21) after virosomal 
vaccination exhibiting protective titers. There were no differences in HI titers if the recipient 
was vaccinated earlier or later than 6 months post transplantation in both cohorts. 
After virosomal vaccination, the median antigen-specific IFNγ production increased 5-fold 
from pre-vaccination to post vaccination (8.7pg/mL to 45.5pg/mL) in response to the. 
A/California/H1N1/2009 antigen (p=0.05). This response is in contrast to the response after 
Figure 9 -δ production of IFN-γ in response to influenza monovalent antigens in 
the two cohorts 
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seasonal non-adjuvanted vaccination, where there was no increase in median IFNγ production 
after vaccination in the response to the A/California/H1N1/2009 antigen (p=0.19). 
The increase in cytokine production from pre to post vaccination response, i.e the 
production response was calculated. The virosomal vaccine induced significantly higher δ-
IFNγ responses (p<0.01) to A/California/7/2009(H1N1) with a trend to (p=0.07) increased  
IFNγ production in response to the generic H1N1 strain (A/Solomon Islands/3/2006(H1N1) 
and a significantly (p=0.02) increased  IFNγ response to B/Brisbane/60/2008 as compared to 
the seasonal non-adjuvanted vaccine. Patients following virosomal vaccination later than 6 
months after HSCT had significantly higher IFNγ production (p<0.001) in response to 
A/California/7/2009(H1N1) and significantly higher δ (delta) (p=0.006) values as compared 
to the control cohort that received the non-adjuvanted vaccine (figure 9). 
The matrix 1 protein specific HLA A*02- GILGFVFTL restricted CD8 T-cells were 
enumerated in a subgroup of patients in the two vaccination cohorts by flow cytometric 
analysis. Analysis of PBMCs from patients vaccinated with the virosomal vaccine exhibited 
increased frequencies of matrix 1 specific CD8 T-cells (p=0.01) measured after vaccination 
while there was no difference 
in the control cohort (p=0.1) 
after non-adjuvanted 
vaccination (figure 10). No 
significant differences were 
observed in the frequency of 
pandemic influenza 
hemagglutinin specific HLA 
A*02- RLATGLRNV 
restricted CD8 T cells in the 
peripheral blood between the 
cohorts. 
The virosomal vaccine did not 
improve the serological 
responses compared to the standard vaccine. This reflect most likely the dysfunctional 
humoral immune response during the first year after stem cell transplantation [274], it is 
possible that a two-dose adjuvanted vaccine might have had a better response as observed 
using the AS03 adjuvanted vaccine [225, 228].  
In contrast to the poor serological responses, we found that the adjuvanted virosomal trivalent 
vaccine was capable to elicit robust IFNγ production in aHSCT patients. And there could be 
several reasons for this improved response: i) the virosome resembles the native viral 
structure and has similar cell entry and functional receptor binding characteristics [275] ii) the 
virosome sufficiently induces the maturation of dendritic cells as measured by up regulation 
of MHC class I, MHC class II, ICAM-1, B7.1, B7.2 and CD40 [276] (iii) the T helper cell 
Figure 10 - Influenza matrix 1 GILGFVFTL specific and HLA-A*02 
restricted CD8 T cells were analysed in the study cohort (n=13) after 
virosomal vaccination 
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and CTL compartment is potently activated by virosome as reflected by increased IFNγ 
production [277, 278]. 
We also observed significant increases in Matrix 1 HLA-A*02 restricted CD8 T-cells in 
blood from patients who received the virosomal vaccine. This could be attributed to the fact 
that both the virosomal and seasonal subunit vaccines are manufactured from purified 
monovalent bulks that could have traces of matrix 1 protein [261-264, 279] that might 
promote matrix 1 specific cellular immune responses. Influenza specific MHC class I 
restricted CD8 T-cells studied previously following non-adjuvanted influenza vaccination 
elicited minimal increases in antigen specific CD8 T-cell frequencies [234]. 
The time to vaccination was a crucial variable with poorer responses in both cohorts prior to 
6 months after HSCT while the virosomal vaccine elicited better responses in the group 
vaccinated >6M after HSCT. This maybe in part due to an improved immunostimulatory 
effect on the PRRs of dendritic cells and macrophages; reflecting a native virus, in the 
absence of B cells after HSCT [275]. The influenza specific cellular immune responses may 
modify the course of the influenza infection, since it has been shown in elderly individuals 
that the risk for influenza disease was comparable in individuals demonstrating a cell-
mediated response alone, an antibody response alone, or both types of responses [235]. 
  
  43 
3.4 Influenza specific CD3+CD8+ cytotoxic lymphocytes reside in precursor 
CD45RA+CCR7+ T-cells in individuals after pandemic influenza (Paper 
IV) 
CD8 T-cells have been implicated in direct killing of influenza-infected cells reducing greatly 
disease severity; a cellular immune response is often correlated with vaccine-induced 
protection [280, 281]. The majority of CD8 T-cell epitopes that have been reported are 
present in the internal conserved proteins of the pandemic influenza [282].We showed 
previously in paper 1 that the AS03 adjuvanted influenza vaccine induced a different humoral 
response profile as compared to the natural pandemic flu infection in the current cohort [283], 
further we asked if the same phenomenon applies to cellular immune responses i.e. if 
pandemic hemagglutinin specific CD8 T-cells generated during a flu infection and after the 
vaccination have different immune memory profiles. 
Nine HLA-A*02 individuals with a positive pandemic 2009 H1N1 RNA Swab and blood 
draws at onset of infection (September-November 2009), 2 weeks after onset of symptoms, as 
well as 6 months post-infection (April-May 2010) were studied. Blood from 8 (age and sex-
matched) HLA-A*02 individuals before (September-November 2009) and 6 months (April-
May 2010) after adjuvanted vaccination against pandemic H1N1 influenza (Pandemrix
®
) 
were used as controls. MHC class I restricted T-cells directed against the newly identified 
pandemic Influenza hemagglutinin peptide RLATGLRNV and the Matrix 1 peptide 
GILGFVFTL. HLA-A*02 restricted CD8 T-cells and their memory phenotype was 
characterized by flow cytometry, defined by CD45RA and CCR7 expression. Whole blood 
influenza antigen specific IFNγ release assays were performed to quantify the effector IFNγ 
production in PBMCs. 
At the onset of pandemic influenza season, the median frequencies of A*02 RLATGLRNV 
hemagglutinin (HA) restricted CD8 T-cells were higher (6.28%, with a trend to significance 
(p=0.05) in the PBMCs from the control group as compared to PBMCs from individuals 
(2.7%) who later contracted a pandemic flu infection. HA specific terminal effector memory 
CD8 T-cells (CD45RA+CCR7-) in the PBMCs from control individuals was higher (45.8%) 
as compared to the PBMCs (21.3 %) in susceptible individuals who later contracted influenza 
infection. These individuals also exhibited higher median frequencies (59.3%) of T-cells 
exhibiting the precursor phenotype characterized by co-expression of CD45RA+ and CCR7+ 
as compared to T-cells from individuals in the control group (28.25%). 
Influenza hemagglutinin specific CD8 T-cells during the pandemic infection were 
predominantly in the precursor phenotype with co-expression of CD45RA+ CCR7+ (median 
55.5%, i.e. significantly higher, p<0.05) than other T-cell compartments (central memory- 3.1 
%, effector memory – 13.1% and terminal effectors – 27.9%). 
Following the pandemic influenza infection, central memory hemagglutinin specific CD8 T–
cells (CD45RA-CCR7+) had a trend to increased frequencies (p=0.05) and a significant 
decrease (p=0.02) in terminal effector (CD45RA+CCR7-) in relation to PBMCs tested prior 
to pandemic influenza infection. Following the pandemrix
®
 vaccination, a significant increase 
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(p=0.03) in the effector hemagglutinin specific CD8 T-cells (CD45RA-CCR7-) and trend to 
decreased precursor hemagglutinin specific CD8 T-cells (CD45RA+CCR7+) in relation to 
PBMCs tested prior to pandemrix
®
 vaccination was observed. Influenza hemagglutinin (pdm 
2009) restricted CD8 T-cells after vaccination are concentrated in the terminally 
differentiated effector pool and significantly different (p=0.003) in relation to PBMCs tested 
from individuals after pandemic influenza infection. 
We did not find any significant differences in the frequencies of Matrix 1 GILGFVFTL. 
HLA-A*02 restricted CD8 T-cells in PBMCs prior to or following either pandemic influenza 
infection or vaccination. Of importance was that M1 specific CD8 T-cells in PBMCs from 
individuals after pandemic influenza exhibited higher frequencies of central memory CD8 T-
cells (p=0.06) compared to the group that was vaccinated in contrast to the PBMCs following 
flu vaccination where the M1 specific CD8 T-cells resided in the terminal effector memory 
pool after Flu vaccination: and significantly higher (p=0.003). 
We observed higher frequencies of influenza hemagglutinin precursor CD8 T-cells in 
PBMCs before pandemic flu infection and a significant increase following pandemic 
influenza infection as compared to PBMCs from individuals after the flu vaccination. This 
could have two implications (i) The presence of these antigen specific cells in this phenotype 
is detrimental to the individual and reportedly can correlate with a symptomatic influenza 
infection as observed in murine models [284] (ii) These are beneficial antigen-experienced T-
cells with a precursor like phenotype that have been observed in other infectious disease 
contexts [285-288]. These antigen-experienced T-cells are able to differentiate into other T-
cell memory and effector CD117+ (c-kit) CD45RA+CCR7+ T-cell subsets with capacity to 
produce IFNγ [289-291]. 
The clinical relevance of such subset has to be further studied and the cytokine patterns have 
to be characterized. Identification of ‘multipotent’ precursor-like memory-cells in the course 
of Flu infection could be clinically relevant, particularly in the development of improved Flu 
vaccines. In conclusion, influenza vaccination with AS03 adjuvanted vaccine induced a 
different memory profile of Influenza specific CD8 T-cells as compared to the natural 
pandemic flu infection. 
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4 CONCLUSIONS  
Influenza infections can represent important complications after aHSCT resulting in lower 
respiratory tract infections and mortality. Preventive strategies such as influenza vaccination 
are therefore important. Since the current immune responses to vaccination are frequently 
suboptimal, we evaluated alternative vaccination systems and vaccination schedules to 
improve vaccination efficacy. In addition we identified correlates of influenza vaccine 
mediated immune responses in immunocompetent individuals. 
In our paper I, we asked if the pandemic influenza infection generated a different humoral 
immune profile as compared to influenza vaccination. 
Our paper I resulted in new insights into the influenza epitope serum IgG recognition patterns 
and these could be clearly linked to clinical endpoints i.e. before and after pandemic influenza 
infection or vaccination. The individuals with symptomatic influenza infection completely 
lacked any serum IgG response to pandemic hemagglutinin linear epitopes studied by our 
technique, which may have contributed to this outcome. Further these individuals had a very 
dominant IgG response to hemagglutinin epitopes from swine H1N1 strains in contrast to the 
individuals who did not have the symptomatic influenza infection. We also found that 
absence of reactivity to pandemic hemagglutinin epitope (251-265) could be a predictor for 
susceptibility to symptomatic pandemic influenza infection. These findings should be further 
characterized retrospectively in serum aliquots from larger cohorts that are available from the 
pandemic H1N1 season of 2009-2010. 
In our paper II, we asked if there is any beneficial effect of pre-transplant influenza 
vaccination on seroprotection early after transplant. 
Pre-transplant recipient vaccination in particular was significantly associated with protective 
responses to H1 and H3 antigens up to day 180 after transplantation. Retention of vaccine 
antigens or antigen-antibody immune complexes in the recipient’s follicular dendritic cells 
[292, 293] post HSCT may drive the proliferation of donor lymphocytes. Another finding 
was that response to vaccination before HSCT was very poor and most patients who had 
seroprotective titers on HSCT day were able to maintain them until d60. We did not notice 
any effect of pre-transplant vaccination on the day 180 vaccination sero-responses, which 
were poor (8 % to antigen B and 20% to antigen H1). An earlier vaccination within three 
months post-transplant would have been beneficial similar to what have been seen in studies 
with other antigens such as tetanus toxoid. 
In our paper III, we asked if an influenza adjuvanted virosomal vaccination would result in 
improved immune responses compared to non-adjuvanted seasonal vaccination in aHSCT 
recipients 
An enhanced cellular immune response to influenza pandemic (pdm) H1N1 antigen 
following a virosomal vaccination as compared to the seasonal non-adjuvanted vaccination 
was found. This can be attributed to the virosomal formulation that reflects closely the native 
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virus in having potent immunostimulatory effects leading to enhanced cellular immune 
responses. We did not see any beneficial effect on the seroresponse rates after virosomal 
vaccination as compared to non-adjuvanted vaccination maybe due to impaired B-cell 
compartments. Further, we observed poor IFNγ and serum HI titers in recipients early after 
transplant (≤6 months), where they are most vulnerable, Additional studies are necessary to 
improve the response rates in this period. 
In our paper IV, we asked if the presence and/or memory phenotype of HLA-A*02 influenza 
pandemic hemagglutinin peptide restricted CD8 T-cells correlate with either symptomatic 
influenza or adjuvanted AS03 vaccination 
Although there were no significant differences in the frequency of HLA-A*02 influenza 
pandemic hemagglutinin peptide restricted CD8 T-cells after pandemic influenza infection 
and vaccination, the δ frequency of antigen specific T-cells was significantly higher after 
adjuvanted vaccination. We also observed that these antigen-specific T-cells belonged to a 
terminally differentiated effector memory phenotype characterized by CD45RA+ CCR7- in 
individuals after vaccination, in contrast to PBMCS obtained from individuals after 
symptomatic influenza infection. Here, the antigen specific T-cells resided in the 
precursor/naïve phenotype characterized by CD45RA+ CCR7+. We conclude that the 
cellular immune signatures are different in a natural influenza infection and vaccination. 
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5 FUTURE PERSPECTIVES 
Influenza infections are a constant threat to immunocompetent and immunosuppressed 
individuals. Improved understanding of protective immune responses will greatly benefit in 
rational vaccine designs. Future work should unravel the functional significance of IgG 
reactivity to VEPGDKITFEATGNL, the epitope on the antigenic site of the pandemic flu 
hemagglutinin. The antigen specific plasma cells from these vaccinated individuals could be 
further characterized using deep sequencing of their antigen receptors and compared to 
plasma cells from individuals after influenza infection. 
Further influenza vaccination studies should address a 2-dose strategy by priming the patient 
early after HSCT (<6M) with an adjuvanted vaccine followed by a yearly boosting 
immunization with a non-adjuvanted vaccine matched for antigens during the influenza 
season. Another strategy could be the vaccination of related donors pre-transplantation with 
an adjuvanted influenza vaccine that may have beneficial seroprotective effect early after 
transplant. A higher dose of influenza vaccine (60µg HA) administered intramuscularly or 
intradermal TIV with regular dose (15µg HA) could also be tested in HSCT patients, which 
may promote superior response as seen in previous studies in older adults [294, 295]. 
Since we identified different memory profiles of influenza of HLA-A*02 influenza pandemic 
hemagglutinin peptide restricted CD8 T-cells in natural influenza infection and vaccination, 
the effector cytokine profiles of these specific cells will have to be addressed, i.e. if a 
symptomatic influenza infection is due to polyfunctionality or vice versa. Deep sequencing of 
the TCR Vβ repertoire would allow visualization of dynamics of TCR usage prior to and 
following pandemic influenza infection/vaccination: it would demonstrate whether the 
existing antigen specific T-cell pool is expanded or rather new clonotypes are being recruited 
upon influenza infection/vaccination The detailed functional analysis of the anti-Flu T-cell 
responses will provide interesting cues whether protective and long-lasting immune responses 
are rather focused (defined by the limited use TCRs directed against the nominal target), or 
rather oligoclonal/polyclonal with several TCRs targeting MHC class I-peptide complexes. 
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